Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Jan A van Noord"'
Autor:
Jan A. van Noord, Pauline V. van Hirtum, Martijn D. de Kruif, Monique van Vliet, Roy T.M. Sprooten
Publikováno v:
Respiratory Medicine, 137, 77-82. Elsevier Saunders
Background and objective Life expectancy data of COPD patients in comparison to the general population are primarily based upon long-term population cohort studies. These studies are limited by a poor definition of clinically significant COPD. The ke
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f41b058b3560d8711881e232be0b217
https://pubmed.ncbi.nlm.nih.gov/29605217
https://pubmed.ncbi.nlm.nih.gov/29605217
Autor:
Tammy McIver, Kirsten McAulay, Jan A. van Noord, Winfried Schröder-Babo, Anna Bodzenta-Lukaszyk
Publikováno v:
Current Medical Research and Opinion. 29:579-588
The potent inhaled corticosteroid, fluticasone propionate (fluticasone), and the long-acting β2-agonist with a rapid onset of action, formoterol fumarate (formoterol), have now been combined in a single aerosol inhaler, fluticasone/formoterol (fluti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5fc3e416e33b2e96336bee46c429112
https://doi.org/10.1185/03007995.2013.772506
https://doi.org/10.1185/03007995.2013.772506
Autor:
Pauline V. van Hirtum, Monique van Vliet, Roy T.M. Sprooten, Martijn D. de Kruif, Jan A. van Noord
Publikováno v:
6.1 Epidemiology.
Background: Most COPD-survival studies have examined either 5 or occasionally 10-year survival. Here, we investigate 15-year survival after an admission for exacerbation of COPD. Knowledge of long term survival and its prognostic factors may lead to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c28580054775f44b361c301d61d31348
https://doi.org/10.1183/13993003.congress-2016.pa3116
https://doi.org/10.1183/13993003.congress-2016.pa3116
Autor:
Theo A. Bantje, Jan A. van Noord, Michael Engel, Winfried Schröder-Babo, Bernd Disse, Martina Gahlemann, Ralf Sigmund, Huib A. M. Kerstjens
Publikováno v:
Journal of Allergy and Clinical Immunology, 128(2), 308-314. MOSBY-ELSEVIER
Background: Some patients with severe asthma remain symptomatic and obstructed despite maximal recommended treatment. Tiotropium, a long-acting inhaled anticholinergic agent, might be an effective bronchodilator in such patients.Objective: We sought
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa10f268e263906b7274753c0c42db6c
https://research.rug.nl/en/publications/0cb22295-8fa1-4b90-9b83-9397be7a0cde
https://research.rug.nl/en/publications/0cb22295-8fa1-4b90-9b83-9397be7a0cde
Autor:
E. Janssens, Achim Mueller, P.J.G. Cornelissen, J.J. Smeets, Jan A. van Noord, Jan Verhaert, Joseph L. Aumann
Publikováno v:
Chest. 129:509-517
The combination of short-acting beta(2)-agonists and anticholinergics in the treatment of COPD has been well documented, but data on combination of long-acting agents are lacking.A randomized, open-label, placebo-controlled, three-way crossover study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c547853200fdf8d2a01f86561c177633
https://doi.org/10.1378/chest.129.3.509
https://doi.org/10.1378/chest.129.3.509
Autor:
Angela Lee, James F. Donohue, Lesley Towse, Steven Kesten, Eric D. Bateman, Stephen J. Langley, Theodore J. Witek, Jan A. van Noord
Publikováno v:
Chest. 122:47-55
Background: Tiotropium, a once-daily anticholinergic, and salmeterol represent two inhaled, long-acting bronchodilators from different pharmacologic classes. A trial was designed to examine the efficacy and safety of both compounds with multiple outc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ebd52f5e9127a1db155fca3f01c0c558
https://doi.org/10.1378/chest.122.1.47
https://doi.org/10.1378/chest.122.1.47
Autor:
C.B. Verkleij, P.J.G. Cornelissen, Jan A. van Noord, Michael Trunk, Stephen T. Horhota, Loek J. Bour, Ashish Sharma
Publikováno v:
The AAPS journal. 17(4)
In vitro Andersen cascade impactor-sized mass (ISM) and aerodynamic fine particle mass (FPM)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::472e3ac7645e545e45b73bb8f0dee209
https://pubmed.ncbi.nlm.nih.gov/25794622
https://pubmed.ncbi.nlm.nih.gov/25794622
Autor:
Jan A. van Noord, Jacques P.H.M. Creemers, Helen Dewberry, Louis P.M. Greefhorst, J.J. Smeets, P.J.G. Cornelissen
Publikováno v:
Respiration. 67:672-678
Background: The phase-out of chlorofluorocarbons (CFCs) for metered dose inhalers (MDIs) has prompted the development of alternative propellants and the design of propellant-free devices for inhalation therapy. Objective: This study was carried out t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e14685e61e1e41553f05529c8f8d4400
https://doi.org/10.1159/000056298
https://doi.org/10.1159/000056298
Autor:
F. Topçu, Masayuki Aihara, Helen Dewberry, Yoshikazu Kawakami, Toyohiro Hirai, Jaime Signes-Costa, Inci Gulmez, Haralambos J. Milionis, H.H. Floch, Hironi Makita, Cenk Babayiğit, D. Mottier, Kunio Dobashi, Atsuko Kamachi, Hasan Bayram, J.J. Smeets, Mitsuru Munakata, H. Inoue, Yasutaka Nakano, H. Nazaroğlu, Ruth Cañizares, Akın Eraslan Balci, H. Bayram, Evangelos Briasoulis, Yasutaka Takubo, Kazuo Chin, Jörg Rüdiger Siewert, Ioannis Peponis, Raymonde Busch, Tom G. Sutedja, H. Aizawa, Takashi Nakamura, Abdurrahman Senyigit, N. Miyazaki, B. Guias, M. Fischer, Hiroshi Kurumaya, A. Bilici, Jan A. van Noord, Kam Sze Tsang, Ichizo Tsujino, Yoshitaka Oku, Hubert J. Stein, A. Şenyiğit, Patrick C. Y. Woo, Leonard Mounyam, Yoshio Tsunezuka, Hiroaki Sakai, Marjolein Drent, Kwok-Yung Yuen, Kenji Miyamoto, Clara G.C. Ooi, M. Ertem, Mustafa Özesmi, José A. Onrubia, Masaharu Nishimura, Chikashi Hiranuma, Sema Oymak, C. Leroyer, M. Gökirmak, P.J.G. Cornelissen, Jan Jacobs, Sylvia Wessels, C. Babayiğit, Shigeo Muro, Kenzo Kawakami, Koichi Nishimura, Michiaki Mishima, Eusebio Chiner, Ramazan Demir, F. Couturaud, R. Işık, Hiroshi Shimizu, J.H. Abalain, Cynthia Huisman, Marios Froudarakis, E. Asan, Henk Thijssen, N. Hara, Masatomo Mori, Ömer Satici, E. Chenu, Jacques P.H.M. Creemers, Ichiro Naruse, M. Coşkunsel, Juan Marco, Nicholas Pavlidis, Tsugio Nakazawa, Hideo Sato, E. Oger, Karl Young, Margaret E. Hodson, Stavros H. Constantopoulos, Louis P.M. Greefhorst, Masato Akiyama, Malik Peiris, Klaas W. van Kralingen, K.M. Müller, Pieter E. Postmus, Juan M. Arriero, B. Mercier, Martin Riedel, María J. Mayol, Fusun Topcu, i.H. Leblebici
Publikováno v:
Respiration. 67:707-712
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f31bef41b7c00dbf2e6757b631008f31
https://doi.org/10.1159/000056310
https://doi.org/10.1159/000056310
Autor:
Stanislav Suskovic, Stephen J. Langley, Arthur Helbling, Alexander G. Chuchalin, Jay Jasan, Jonathan A. Leff, Jan A. van Noord, Martino Laurenzi, Joris Menten, Cesar Villaran, Kulasiri A. Gunawardena, Tak H. Lee, Shane J. O’Neill
Publikováno v:
Journal of Allergy and Clinical Immunology. 104:547-553
Background: Montelukast, a leukotriene receptor antagonist, and salmeterol, a long-acting β 2 -receptor agonist, each have demonstrated benefits in the treatment of exercise-induced bronchoconstriction (EIB) in short-term studies. Direct comparisons
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3752f2759e8feb34ed776ba16abdad2a
https://doi.org/10.1016/s0091-6749(99)70322-2
https://doi.org/10.1016/s0091-6749(99)70322-2